Vice Provost and Dean of Research
Showing 1,501-1,520 of 2,475 Results
-
Chris Mentzel
Managing Director of Research and Campus Engagement, Institute for Human-Centered Artificial Intelligence (HAI)
BioChris leads Stanford’s efforts in research and early-career development around data science and data-driven discovery, engaging the entire campus in advancing and applying new data science and AI theory and practice to accelerate research.
Previously, Chris started and led the Moore Foundation's Data-Driven Discovery Initiative, an $80 million effort within the Science Program to enable data scientists to turn the scientific data deluge into opportunities to address some of today's most important research questions. He also led the grants administration department and worked as senior network engineer for the foundation. Chris has held positions as a systems engineer and integrator at the University of California, Berkeley, and at various Internet consulting firms in the Bay Area. An active member of the broader big data and open science communities, Chris serves on a number of advisory boards and program committees and speaks frequently at conferences and workshops on topics related to data-driven research.
Chris received a B.A. in mathematics from the University of California, Santa Cruz, and an M.Sc. in management science and engineering at Stanford University. -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Everett Meyer
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)
Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
-
Inger Hultgren Meyer
Sr. Industrial Contracts Officer, Office of Technology Licensing (OTL)
BioInger is a Senior Industrial Contracts Officer in the Industrial Contracts Office within Stanford’s Office of Technology Licensing. She has over 14 years of experience as a lawyer at law firms and companies in the technology, health care, and consumer products industries in the U.S. and Europe. Before joining Stanford, Inger was an Associate General Counsel at Meta Platforms, Inc. where she advised Meta’s research and engineering teams on IP and other issues arising out of academic collaborations and drafted and negotiated a variety of complex academic collaboration agreements with university partners. Inger holds a B.A. in Government from Cornell University and a J.D. from George Washington University Law School.
-
Timothy Meyer
Stanford University Professor of Nephrology, Emeritus
Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.
-
Sara Michie
Professor of Pathology (Research), Emerita
Current Research and Scholarly InterestsLymphocyte/endothelial cell adhesion mechanisms involved in lymphocyte migration to sites of inflammation; regulation of expression of endothelial cell adhesion molecules.
-
Emmanuel Mignot, MD, PhD
Craig Reynolds Professor of Sleep Medicine and Professor, by courtesy, of Genetics and of Neurology and Neurological Sciences
Current Research and Scholarly InterestsThe research focus of the laboratory is the study of sleep and sleep disorders such as narcolepsy and Kleine Levin syndrome. We also study the neurobiological and genetic basis of the EEG and develop new tools to study sleep using nocturnal polysomnography. Approaches mostly involve human genetic studies (GWAS, sequencing), EEG signal analysis (deep learning), and immunology (narcolepsy is an autoimmune disease of the brain). We also work on autoimmune encephalitis.
-
Paul Milgrom
Shirley R. and Leonard W. Ely, Jr. Professor in the School of Humanities and Sciences, Professor of Economics, Senior Fellow at SIEPR and Professor, by courtesy, of Economics at the GSB and of Management Science and Engineering
BioPaul Milgrom is the Shirley and Leonard Ely professor of Humanities and Sciences in the Department of Economics at Stanford University and professor, by courtesy, in the Stanford Graduate School of Business and in the Department of Management Sciences and Engineering. Born in Detroit, Michigan on April 20, 1948, he is a member of both the National Academy of Sciences and the American Academy of Arts and Sciences and a winner of the 2008 Nemmers Prize in Economics, the 2012 BBVA Frontiers of Knowledge award, the 2017 CME-MSRI prize for Innovative Quantitative Applications, and the 2018 Carty Award for the Advancement of Science.
Milgrom is known for his work on innovative resource allocation methods, particularly in radio spectrum. He is coinventor of the simultaneous multiple round auction and the combinatorial clock auction. He also led the design team for the FCC's 2017 incentive auction, which reallocated spectrum from television broadcast to mobile broadband.
According to his BBVA Award citation: “Paul Milgrom has made seminal contributions to an unusually wide range of fields of economics including auctions, market design, contracts and incentives, industrial economics, economics of organizations, finance, and game theory.” As counted by Google Scholar, Milgrom’s books and articles have received more than 80,000 citations.
Finally, Milgrom has been a successful adviser of graduate students, winning the 2017 H&S Dean's award for Excellence in Graduate Education. -
Carlos Milla
Professor of Pediatrics (Pulmonary Medicine) and, by courtesy, of Medicine (Pulmonary, Allergy and Critical Care Medicine)
Current Research and Scholarly InterestsAt Stanford University I developed and currently direct the CF Translational Research Center. The overarching goal of the center is to provide the groundwork to streamline, accelerate, and promote the translation of basic discoveries into effective therapies and interventions to benefit patients affected by cystic fibrosis. My laboratory group currently has three main lines of investigation: respiratory cell biology in CF; remote biochemical monitoring; and lung physiology in young children.
-
D. Craig Miller, M.D.
Thelma and Henry Doelger Professor of Cardiovascular Surgery, Emeritus
Current Research and Scholarly InterestsCardiac and heart valve disease with experimental laboratory large animal projects focused on the investigation of left ventricular and cardiac mechanics, bioenergetics, and LV and mitral valve physiology and pathophysiology. Current thrust is aimed at understanding the mitral valve and subvalvular mitral apparatus and transmural LV wall strains, thickening, and myolaminar fiber-sheet mechanics.
Clinical research interests include thoracic aortic diseases (aortic dissection, aneurysm) and cardiac valvular disease, including surgical treatment, endovascular thoracic aortic stent-graft repair, mitral valve repair, and valve-sparing aortic root replacement. -
Arnold Milstein
Professor of Medicine (General Medical Discipline)
Current Research and Scholarly InterestsDesign national demonstration of innovations in care delivery that provide more with less. Informed by research on AI-assisted clinical workflow, positive value outlier analysis and triggers of loss aversion bias among patients and clinicians.
Research on creation of a national index of health system productivity gain. -
Paul Salomon Mischel
Fortinet Founders Professor and Professor, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy research bridges cancer genetics, signal transduction and cellular metabolism as we aim to understand the molecular mechanisms that drive cancer development, progression, and drug resistance. We have made a series of discoveries that have identified a central role for ecDNA (extrachromosomal DNA) in cancer development, progression, accelerated tumor evolution and drug resistance.
